Bayer stock has delivered a strong 74.5% return over the past year, yet broader valuation checks still suggest the shares screen as relatively cheap rather than fully pricing in that strength.
- Over the last 12 months, Bayer has returned 74.5%. This puts recent share price momentum front and center for anyone assessing whether the current level is justified.
- The new collaboration with Kairos Pharma around XOFIGO in metastatic prostate cancer can support longer term revenue expectations. At the same time, execution risk on clinical outcomes and commercial uptake may still weigh on how much value investors are willing to ascribe today.
- Bayer passes most of Simply Wall St's valuation checks, with 5 out of 6 suggesting the stock looks inexpensive versus underlying fundamentals.
The issue now is whether Bayer's current price still leaves a reasonable margin between what investors pay today and what the fundamentals appear to support.
Is Bayer a Bargain on Sales?
The P/S multiple suits Bayer because revenue is often a cleaner yardstick than earnings for large pharma groups with heavy research and legal costs. Bayer trades on a P/S of about 1.0x, which is well below the Pharmaceuticals industry average of 2.6x and also sits under the peer group average of 3.1x.
The fair P/S ratio for Bayer, based on its size, margins and risk profile, is estimated at about 2.2x. That is more than double the current 1.0x, which suggests the market price is not fully reflecting the sales base investors get access to at today’s valuation. Despite the recent collaboration with Kairos Pharma drawing attention to Bayer’s oncology pipeline, the stock still trades at a discount to both the industry and this tailored fair multiple.
On the P/S multiple, Bayer stock appears undervalued compared with both its sector and a more tailored fair value benchmark.
See what the numbers say about this price — find out in our valuation breakdown.
The Bayer Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Bayer valuation puzzle leaves off and explain which growth, margin and earnings paths would need to occur for the stock to be worth materially more or less than today’s price. Each narrative connects its number to a clear view of how Bayer's revenue mix, profitability and risk profile might change next, which you can revisit as new information about the business becomes available.
Community views on Bayer sit far apart, with some investors focused on litigation relief and others on lingering earnings and balance sheet pressure.
Bull case: 12% undervalued
"Progress on litigation containment, including large case settlements at low average cost, strategic provision management, and an articulated multi-pronged legal strategy with a target to largely resolve legacy glyphosate and PCB exposures by end-2026, has the potential to remove a major overhang on earnings and valuation, signaling a medium-term inflection in net margin, earnings quality, and investor sentiment…"
Read the full Bull Case to see why Bayer could be undervalued
Bear case: 21% overvalued
"Os litígios relacionados ao glifosato (Roundup) continuam a ser um fardo significativo nas finanças da Bayer, com impactos que se estendem a 2026…"
Read the full Bear Case to see why Bayer could be overvalued
Do you think there's more to the story for Bayer? Head over to our Community to see what others are saying!
The Bottom Line
For Bayer, the current picture still leans toward undervalued on market multiples, with the P/S discount pointing to a stock that is yet to fully reflect its existing revenue base. The key question is whether that gap closes through a higher multiple or through fundamentals shifting in a way that justifies today’s pricing. The crux of the debate is whether litigation and execution risks ease enough for investors to re-rate Bayer, or whether the present discount proves to be a value trap that correctly prices those pressures.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com